The Food and Drug Administration, or FDA, has announced a newly approved treatment for agitation associated with Alzheimer’s disease. The medication, Dextromethorphan HBr/bupropion HCl, is already approved for major depressive disorder and could offer significant relief for one of the most troubling symptoms of cognitive decline.
Seven million Americans are already living with Alzheimer’s disease. By 2050, that count could rise to nearly 13 million. Even among the many challenges presented by Alzheimer’s disease, agitation can be very taxing for patients and care partners. Restlessness, irritability, and verbal and physical aggression are common in patients with Alzheimer’s, creating further emotional strain for patients and their families. Behaviors associated with agitation, anger and aggression make administering care more difficult, both at home and in institutional settings.
Confusion, pain, depression, fatigue, stress and even medication interactions can exacerbate agitation in distressed patients. Severe and disruptive outbursts may threaten the physical safety of family members. Until recently, not much could be done medically to manage these symptoms.
First-of-Its-Kind Treatment
This medication is the first antidepressant of its kind approved for treating agitation in Alzheimer’s patients. Older treatments for this indication have been antipsychotics, powerful drugs designed to treat severe mental and behavioral challenges. The side effects can be profound, compounding loss of cognitive function and physical independence. A new treatment option could provide hope and stability for years longer than traditional treatments.
For years, caregivers and patient advocates have called for increased investment and research around behavioral symptoms that impact Alzheimer’s patients’ quality of life. Agitation symptoms will touch an estimated two-thirds of patients, and a minority of patients may be violent toward caregivers. More treatment options allow clinicians to customize treatments to a patient’s specific needs.
The Next Challenge Is Access
The medication is expected to be available for this new indication in early June. Ultimately, insurance coverage, affordability, and clinician awareness of this new treatment will shape how it is adopted by those living with Alzheimer’s.
For families navigating the daily challenges of Alzheimer’s care, every additional option matters. Continued innovation and sustained support for access may help improve quality of life for both patients and caregivers alike.
